Translational Pharmacology of CNS and Metabolic Disorders for Testing New Modality Therapies

Animal studies may provide a close approximation to humans when addressing the key challenge of clinical translatability. In the preclinical setting, new insights into disease models and mechanisms are crucial to efficacy studies.

In this webinar, Dr. Deming Xu, Chief Pharmacologist, Executive Director, and Head of In Vivo Pharmacology of WuXi AppTec Discovery Biology will share our experiences and insights of the mechanistic aspects of preclinical pharmacology in the areas of neurodegenerative diseases, NASH, and metabolic disorders (involving PCSK9, in particular). Additional discussion will focus on how such insights are used in testing new modalities such as oligonucleotides and AAV that target the CNS or the liver.